Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in TaxesChange in TaxesChange in Working CapitalChange in Working CapitalDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet Income
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Change in Working Capital (2016 - 2022)

Trinity Biotech's Change in Working Capital history spans 14 years, with the latest figure at -$1.3 million for Q1 2022.

  • On a quarterly basis, Change in Working Capital fell 170.05% to -$1.3 million in Q1 2022 year-over-year; TTM through Mar 2022 was -$1.3 million, a 170.05% decrease, with the full-year FY2025 number at -$186000.0, changed N/A from a year prior.
  • Change in Working Capital hit -$1.3 million in Q1 2022 for Trinity Biotech, up from -$5.0 million in the prior quarter.
  • Over the last five years, Change in Working Capital for TRIB hit a ceiling of $10.2 million in Q4 2020 and a floor of -$7.6 million in Q4 2018.
  • Historically, Change in Working Capital has averaged -$1.4 million across 5 years, with a median of -$2.1 million in 2019.
  • Biggest five-year swings in Change in Working Capital: tumbled 539.84% in 2018 and later skyrocketed 1376.88% in 2020.
  • Tracing TRIB's Change in Working Capital over 5 years: stood at -$7.6 million in 2018, then skyrocketed by 89.52% to -$796000.0 in 2019, then skyrocketed by 1376.88% to $10.2 million in 2020, then tumbled by 148.99% to -$5.0 million in 2021, then surged by 74.25% to -$1.3 million in 2022.
  • Business Quant data shows Change in Working Capital for TRIB at -$1.3 million in Q1 2022, -$5.0 million in Q4 2021, and -$3.1 million in Q3 2021.